Your AI-Trained Oncology Knowledge Connection!

Marc Peeters, MD, PhD

home / authors / marc-peeters-md-phd

Articles

Dr. Peeters Discusses the Efficacy and Safety of Panitumumab Versus Cetuximab in CRC

August 19th 2014

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the efficacy and safety of panitumumab versus cetuximab as seen in the ASPECCT trial in colorectal cancer (CRC).

Dr. Peeters on the Frequency of S492R Mutations Following EGFR Inhibition in mCRC

Marc Peeters, MD, PhD

June 27th 2014

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the frequency of S492R mutations found in patients with metastatic colorectal cancer patients who were treated with panitumumab or cetuximab monotherapy.

Dr. Peeters on the Future of Colorectal Cancer

Marc Peeters, MD, PhD

March 11th 2014

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the future of the treatment of colorectal cancer.

Dr. Peeters on KRAS/NRAS Mutations in mCRC

Marc Peeters, MD, PhD

February 6th 2014

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses an analysis of RAS mutations in the phase III study 20050181, which compared panitumumab plus FOLFIRI versus FOLFIRI for second-line treatment of mCRC

Dr. Peeters on the Utility of Aflibercept in CRC

Marc Peeters, MD, PhD

October 22nd 2013

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the utility of aflibercept in patients with advanced colorectal cancer.

Dr. Marc Peeters on the Aflibercept Toxicity Profile

Marc Peeters, MD, PhD

July 9th 2013

Marc Peeters, MD, PhD, from the Antwerp University Hospital, discusses the importance of properly managing the toxicities associated with aflibercept when treating patients with metastatic colorectal cancer.